Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of PCSK9 Inhibitors market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of PCSK9 Inhibitorsmarket, defines the market attractiveness level of PCSK9 Inhibitors market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of PCSK9 Inhibitors industry, describes the types of PCSK9 Inhibitors market, the applications of major players and the market size, and deeply analyzes the current situation of the global PCSK9 Inhibitors market and the development prospects and opportunities of PCSK9 Inhibitors industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global PCSK9 Inhibitors market in Chapter 13.
By Player:
Amgen
Pfizer
Ionis Pharmaceuticals
Affiris
Novartis
Alnylam
Merck
Roche
BMS
AstraZeneca
Eli Lilly
Sanofi
Daiichi Sankyo
Cyon Therapeutics
By Type:
Epatha Evolocumab
Praluent Alirocumab
Bococizumab
Others
By End-User:
Clinical Application
Drug Development
Other
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 PCSK9 Inhibitors Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 PCSK9 Inhibitors Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 PCSK9 Inhibitors Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 PCSK9 Inhibitors Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise PCSK9 Inhibitors Market Analysis and Outlook to 2022
-
7.1 Global PCSK9 Inhibitors Consumption (2017-2022)
-
7.2 United States PCSK9 Inhibitors Consumption (2017-2022)
-
7.3 Europe PCSK9 Inhibitors Consumption (2017-2022)
-
7.4 China PCSK9 Inhibitors Consumption (2017-2022)
-
7.5 Japan PCSK9 Inhibitors Consumption (2017-2022)
-
7.6 India PCSK9 Inhibitors Consumption (2017-2022)
-
7.7 South Korea PCSK9 Inhibitors Consumption (2017-2022)
8 Region and Country-wise PCSK9 Inhibitors Market Analysis and Outlook to 2028
-
8.1 Global PCSK9 Inhibitors Consumption Forecast (2022-2028)
-
8.2 United States PCSK9 Inhibitors Consumption Forecast (2022-2028)
-
8.3 Europe PCSK9 Inhibitors Consumption Forecast (2022-2028)
-
8.4 China PCSK9 Inhibitors Consumption Forecast (2022-2028)
-
8.5 Japan PCSK9 Inhibitors Consumption Forecast (2022-2028)
-
8.6 India PCSK9 Inhibitors Consumption Forecast (2022-2028)
-
8.7 South Korea PCSK9 Inhibitors Consumption Forecast (2022-2028)
9 Global PCSK9 Inhibitors Market Outlook by Types and Applications to 2022
-
9.1 Global PCSK9 Inhibitors Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Epatha Evolocumab Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Praluent Alirocumab Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Bococizumab Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global PCSK9 Inhibitors Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Clinical Application Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Drug Development Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Global PCSK9 Inhibitors Market Outlook by Types and Applications to 2028
-
10.1 Global PCSK9 Inhibitors Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Epatha Evolocumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Praluent Alirocumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Bococizumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global PCSK9 Inhibitors Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Clinical Application Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Drug Development Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
11 Global PCSK9 Inhibitors Import and Export Analysis (Top 5 Countries)
-
11.1 Global PCSK9 Inhibitors Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global PCSK9 Inhibitors Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 PCSK9 Inhibitors Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global PCSK9 Inhibitors Market Competitive Analysis
-
14.1 Amgen
-
14.1.1 Amgen Company Details
-
14.1.2 Amgen PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Amgen PCSK9 Inhibitors Product and Service
-
14.2 Pfizer
-
14.2.1 Pfizer Company Details
-
14.2.2 Pfizer PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Pfizer PCSK9 Inhibitors Product and Service
-
14.3 Ionis Pharmaceuticals
-
14.3.1 Ionis Pharmaceuticals Company Details
-
14.3.2 Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Ionis Pharmaceuticals PCSK9 Inhibitors Product and Service
-
14.4 Affiris
-
14.4.1 Affiris Company Details
-
14.4.2 Affiris PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Affiris PCSK9 Inhibitors Product and Service
-
14.5 Novartis
-
14.5.1 Novartis Company Details
-
14.5.2 Novartis PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Novartis PCSK9 Inhibitors Product and Service
-
14.6 Alnylam
-
14.6.1 Alnylam Company Details
-
14.6.2 Alnylam PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Alnylam PCSK9 Inhibitors Product and Service
-
14.7 Merck
-
14.7.1 Merck Company Details
-
14.7.2 Merck PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Merck PCSK9 Inhibitors Product and Service
-
14.8 Roche
-
14.8.1 Roche Company Details
-
14.8.2 Roche PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Roche PCSK9 Inhibitors Product and Service
-
14.9 BMS
-
14.9.1 BMS Company Details
-
14.9.2 BMS PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 BMS PCSK9 Inhibitors Product and Service
-
14.10 AstraZeneca
-
14.10.1 AstraZeneca Company Details
-
14.10.2 AstraZeneca PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 AstraZeneca PCSK9 Inhibitors Product and Service
-
14.11 Eli Lilly
-
14.11.1 Eli Lilly Company Details
-
14.11.2 Eli Lilly PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Eli Lilly PCSK9 Inhibitors Product and Service
-
14.12 Sanofi
-
14.12.1 Sanofi Company Details
-
14.12.2 Sanofi PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 Sanofi PCSK9 Inhibitors Product and Service
-
14.13 Daiichi Sankyo
-
14.13.1 Daiichi Sankyo Company Details
-
14.13.2 Daiichi Sankyo PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.13.3 Daiichi Sankyo PCSK9 Inhibitors Product and Service
-
14.14 Cyon Therapeutics
-
14.14.1 Cyon Therapeutics Company Details
-
14.14.2 Cyon Therapeutics PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.14.3 Cyon Therapeutics PCSK9 Inhibitors Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of PCSK9 Inhibitors
-
Figure PCSK9 Inhibitors Picture
-
Table Global PCSK9 Inhibitors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global PCSK9 Inhibitors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global PCSK9 Inhibitors Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global PCSK9 Inhibitors Consumption by Country (2017-2022)
-
Figure United States PCSK9 Inhibitors Consumption and Growth Rate (2017-2022)
-
Table Europe PCSK9 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure China PCSK9 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Japan PCSK9 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure India PCSK9 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure South Korea PCSK9 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global PCSK9 Inhibitors Consumption Forecast by Country (2022-2028)
-
Figure United States PCSK9 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe PCSK9 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure China PCSK9 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan PCSK9 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure India PCSK9 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea PCSK9 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Epatha Evolocumab Consumption and Growth Rate (2017-2022)
-
Figure Global Praluent Alirocumab Consumption and Growth Rate (2017-2022)
-
Figure Global Bococizumab Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Clinical Application Consumption and Growth Rate (2017-2022)
-
Figure Global Drug Development Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Epatha Evolocumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Praluent Alirocumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Bococizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinical Application Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Drug Development Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Table Global PCSK9 Inhibitors Import by Region (Top 5 Countries) (2017-2028)
-
Table Global PCSK9 Inhibitors Export by Region (Top 5 Countries) (2017-2028)
-
Table Amgen (Foundation Year, Company Profile and etc.)
-
Table Amgen PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen PCSK9 Inhibitors Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer PCSK9 Inhibitors Product and Service
-
Table Ionis Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Ionis Pharmaceuticals PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ionis Pharmaceuticals PCSK9 Inhibitors Product and Service
-
Table Affiris (Foundation Year, Company Profile and etc.)
-
Table Affiris PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Affiris PCSK9 Inhibitors Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis PCSK9 Inhibitors Product and Service
-
Table Alnylam (Foundation Year, Company Profile and etc.)
-
Table Alnylam PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alnylam PCSK9 Inhibitors Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck PCSK9 Inhibitors Product and Service
-
Table Roche (Foundation Year, Company Profile and etc.)
-
Table Roche PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche PCSK9 Inhibitors Product and Service
-
Table BMS (Foundation Year, Company Profile and etc.)
-
Table BMS PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table BMS PCSK9 Inhibitors Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca PCSK9 Inhibitors Product and Service
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly PCSK9 Inhibitors Product and Service
-
Table Sanofi (Foundation Year, Company Profile and etc.)
-
Table Sanofi PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi PCSK9 Inhibitors Product and Service
-
Table Daiichi Sankyo (Foundation Year, Company Profile and etc.)
-
Table Daiichi Sankyo PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo PCSK9 Inhibitors Product and Service
-
Table Cyon Therapeutics (Foundation Year, Company Profile and etc.)
-
Table Cyon Therapeutics PCSK9 Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cyon Therapeutics PCSK9 Inhibitors Product and Service
-
